# PLX catalysts: Protalix BioTherapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/plx/catalysts

> Protalix BioTherapeutics, Inc. (PLX) has 2 upcoming catalysts. The next is the PRX-115 primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Protalix BioTherapeutics, Inc. |
| Ticker | PLX (NYSE) |
| SEC CIK | 1006281 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/plx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2022 | [Protalix BioTherapeutics, Inc. topline data readout](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed, positive | "The final analysis confirmed the positive top-line results (announced in April 2022) and favorable tolerability profile." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1006281/000155837024015612/plx-20240930x10q.htm)) |
| April 4, 2022 | [Elfabrio (pegunigalsidase alfa) topline data readout](https://sec-api.dev/pdufa/pegunigalsidase-alfa) | PLX | Fabry disease | completed, positive | "On April 4, 2022, we, together with our development and commercialization partner for PRX-102, Chiesi, announced positive topline results from our BALANCE study, a pivotal phase III clinical trial evaluating PRX-102, 1 mg/kg, administered every two weeks, compared to agalsidase beta (Fabrazyme®) for the treatment of Fabry disease." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1006281/000110465925024457/tm259263d1_424b5.htm)) |
| November 9, 2022 | [Elfabrio (pegunigalsidase alfa) NDA/BLA submission](https://sec-api.dev/pdufa/pegunigalsidase-alfa) | PLX |  | completed | "On November 9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1006281/000110465925110824/plx-20250930x10q.htm)) |
| Mar 2023 | [PRX-115 trial start](https://sec-api.dev/pdufa/prx-115) | PLX |  | completed | "In March 2023, we initiated a phase I First-in-Human clinical trial of PRX-115." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003039/plx-20241231x10k.htm)) |
| Mar 2024 | [PRX-115 trial start](https://sec-api.dev/pdufa/prx-115) | PLX |  | completed | "In March 2024, the Company initiated a phase I First-in-Human clinical trial of PRX-115." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1006281/000155837024015612/plx-20240930x10q.htm)) |
| November 14, 2024 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, November 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837024015608/plx-20241114xex99d1.htm)) |
| March 17, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317xex99d1.htm)) |
| May 9, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/plx-20250509xex99d1.htm)) |
| 2H 2025 | [PRX-115 trial start](https://sec-api.dev/pdufa/prx-115) | PLX | gout during the second half of 2025 | scheduled | ""We are pleased with the promising results from our first-in-human study of our gout candidate, PRX-115, in adult volunteers with elevated uric acid levels, and hope to build on this momentum with the goal of initiating a phase II clinical trial in patients with gout during the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317xex99d1.htm)) |
| August 14, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, August 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/plx-20250814xex99d1.htm)) |
| Sep 2025 | [PRX-115 NDA/BLA acceptance](https://sec-api.dev/pdufa/prx-115) | PLX |  | completed | "FDA accepted BLA for review Sept 2025)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926013498/plx-20260211xex99d1.htm)) |
| November 13, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, November 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/plx-20251113xex99d1.htm)) |
| March 18, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, March 18, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the fiscal year ended December 31, 2025, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/plx-20260318xex99d1.htm)) |
| May 13, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, May 13, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513xex99d1.htm)) |
| Jun 2026 | [Protalix BioTherapeutics, Inc. PDUFA date](https://sec-api.dev/companies/plx/catalysts) | PLX | chronic refractory gout | scheduled | "For example, Swedish Orphan Biovitrum AB (Sobi) has developed Pegadriscase (NASP) for the treatment of chronic refractory gout that recently completed a Phase 3 clinical trial, and the FDA has set a Prescription Drug User Fee Act (PDUFA) target action date in June 2026 for its review and decision on NASP." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/plx-20251231x10k.htm)) |
| August 12, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, August 12, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812xex99d1.htm)) |
| November 10, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, November 10, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926124761/plx-ex99d1.htm)) |
| December 2027 | [PRX-115 primary completion](https://sec-api.dev/pdufa/prx-115) | PLX | Gout | scheduled | "NCT07280156 (A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Protalix." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07280156)) |
| Dec 2027 to Mar 2028 | [PRX-115 topline data readout](https://sec-api.dev/pdufa/prx-115) | PLX | Gout | scheduled | "NCT07280156 (A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Protalix." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07280156)) |

## Drugs

- [Elfabrio (pegunigalsidase alfa)](https://sec-api.dev/pdufa/pegunigalsidase-alfa): fabry disease
- [PRX-115](https://sec-api.dev/pdufa/prx-115): uncontrolled gout, gout during the second half of 2025, Gout

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/plx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PLX catalysts: Protalix BioTherapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/plx/catalysts

```bibtex
@misc{secapidev_companies_plx_catalysts_20261116,
  title        = {PLX catalysts: Protalix BioTherapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/plx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_plx_catalysts_20261116","title":"PLX catalysts: Protalix BioTherapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/plx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
